Orbital and eyelid b-cell lymphoma: A multicenter retrospective study

Gustavo Savino, Giulia Midena, Maria Antonietta Blasi, Remo Battendieri, Gabriela Grimaldi, Martina Maceroni, Fausto Tranfa, Pasquale Napolitano, Paola Napolitano, Vittoria Lanni, Adriana Iuliano

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Background: The aim of this study was to analyze patients diagnosed, staged and treated for orbital and eyelid B-cell lymphoma (OEL). Methods: One hundred and forty-one cases of OEL were included in this study. Primary endpoints were to analyze the histopathologic findings, the main risk factors and the type of treatment and to correlate them with recurrence of OEL. The secondary endpoint was to determine the progression-free survival (PFS) time. Results: Extranodal marginal zone B-cell lymphoma was the most frequent subtype (66%), followed by small lymphocytic lymphoma (12.7%), diffuse large B-cell lymphoma (DLBCL) (9.2%), follicular lymphoma (6.6%), mantle cell lymphoma (4.3%) and Burkitt lymphoma (1.2%). The probability of relapse was influenced by the histopathologic subtype DLBCL (OR = 7.7, 95% CI 1.8–32.3) and treatment with chemotherapy (OR = 14.9, 95% CI 2.6–83.7). Multivariate analysis showed that the histopathologic subtype DLBCL and chemotherapy treatment retained statistical significance for a poorer PFS, with hazard ratios of 8.581 (p = 0.0112) and 9.239 (p = 0.0094), respectively. Conclusions: Five lymphoma subtypes were found in patients with OEL. The histopathologic subtype and the type of treatment were found to be the main factors influencing treatment outcome.
Lingua originaleEnglish
pagine (da-a)1-11
Numero di pagine11
Stato di pubblicazionePubblicato - 2020


  • Eyelid lymphoma
  • Ocular adnexal lymphoma
  • Ocular lymphoma prognosis
  • Ocular lymphoma treatment
  • Orbital lymphoma
  • Orbital neoplasms
  • Precision medicine


Entra nei temi di ricerca di 'Orbital and eyelid b-cell lymphoma: A multicenter retrospective study'. Insieme formano una fingerprint unica.

Cita questo